EPREX (erythropoietin alfa)
will be the only funded brand of
erythropoietin in the community
and the only brand of erythropoietin
able to be used in NZ DHB hospitals
from 01 Mar 2015 to 28 Feb 2018.
Access to the drug will be
widened to include patients with
myelodysplasia and patients for
whom blood transfusion is not a
viable treatment option (hospital
only).The above article was sent to subscribers in Pharmacy Daily's issue from 07 Aug 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 Aug 14
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.